Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young.

Autor: Kovács G; Syreon Research Institute, Budapest, 1142, Hungary., Nagy D; Syreon Research Institute, Budapest, 1142, Hungary., Szilberhorn L; Syreon Research Institute, Budapest, 1142, Hungary., Zelei T; Syreon Research Institute, Budapest, 1142, Hungary., Gaál Z; Fourth Department of Medicine, Jósa András Teaching Hospital, Nyíregyháza, 4400, Hungary., Vellekoop H; Institute for Medical Technology Assessment, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands., Huygens S; Institute for Medical Technology Assessment, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands., Versteegh M; Institute for Medical Technology Assessment, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands., Mölken MR; Institute for Medical Technology Assessment, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 17383000 DR, Rotterdam, The Netherlands., Koleva-Kolarova R; Health Economics Research Centre, University of Oxford, Oxford, OX3 7LF, UK., Tsiachristas A; Health Economics Research Centre, University of Oxford, Oxford, OX3 7LF, UK., Wordsworth S; Health Economics Research Centre, University of Oxford, Oxford, OX3 7LF, UK., Nagy B; Syreon Research Institute, Budapest, 1142, Hungary.; Center for Health Technology Assessment, Semmelweis University, Budapest, 1091, Hungary.
Jazyk: angličtina
Zdroj: Personalized medicine [Per Med] 2023 Jul; Vol. 20 (4), pp. 375-385. Date of Electronic Publication: 2023 Sep 11.
DOI: 10.2217/pme-2023-0023
Abstrakt: Maturity-onset diabetes of the young (MODY) is often misdiagnosed as Type I or II diabetes. This study was designed to assess the cost-effectiveness of MODY screening strategies in Hungary, which included a recent genetic test compared with no routine screening for MODY. A simulation model that combined a decision tree and an individual-level Markov model was constructed to assess the costs per quality-adjusted life year of screening strategies. Stratifying patients based on age and insulin treatment followed by a risk assessment questionnaire, a laboratory test and genetic testing was the most cost-effective strategy, saving EUR 12 and generating 0.0047 quality-adjusted life years gained per screened patient. This screening strategy could be considered for reimbursement, especially in countries with limited resources.
Databáze: MEDLINE